Saturday 17 October 2026
Export DXR’s income statement to Excel — free account
Daxor Corporation
DXR Healthcare Medical Instruments & Supplies
Revenue growth for five consecutive years.
10.05
0.15
−1.47%
Follow DXR
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | |
|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 15.68 | 3.67 |
P/S ratio |
24.80 | 12.90 | 0.00 | 82.18 | 0.00 | 0.00 | 0.00 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
(36.23) | (18.84) | (133.30) | (16.49) | (31.93) | (31.45) | (19.78) |
P/B ratio |
0.99 | 0.52 | 2.35 | 2.76 | 3.22 | 2.15 | 1.27 |
Price to Tangible BV |
0.99 | 0.52 | 2.35 | 2.76 | 3.22 | 2.15 | 1.27 |
EV/Sales |
7.08 | (4.82) | (58.90) | 85.27 | (49.34) | (9.35) | (13.47) |
EV/EBITDA |
0.00 | 1.27 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(1.57) | 1.07 | (12.05) | (10.77) | (10.79) | (8.97) | (6.35) |
EV/FCF |
(1.54) | 1.05 | (12.05) | (10.77) | (10.79) | (8.97) | (6.35) |
Quick Ratio |
0.00 | 0.00 | — | — | 0.00 | 0.00 | — |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Debt/Assets |
13.58% | 22.45% | 25.27% | 9.45% | 1.03% | 12.10% | 4.06% |
Debt/Equity |
0.18 | 0.32 | 0.34 | 0.11 | 0.01 | 0.14 | 0.04 |
Asset Turnover |
0.03 | (0.07) | (0.07) | 0.11 | (0.18) | (0.13) | (0.01) |
Operating CF/Net income |
0.91 | 1.83 | 1.49 | 4.19 | 1.65 | (0.60) | (0.67) |
| 9.78% | (8.52%) | (6.61%) | (3.84%) | (11.99%) | 25.79% | 20.66% | |
| 7.01% | (6.21%) | (4.80%) | (3.11%) | (11.09%) | 22.86% | 18.75% | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
0.90 | 1.73 | (0.15) | (0.04) | (0.02) | (0.08) | (0.04) |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 9.21 | 19.80 |
Earnings Yield |
(19.88%) | (38.24%) | (19.15%) | (3.83%) | (4.72%) | 6.38% | 27.22% |
Free Cash Flow Yield |
(18.49%) | (35.56%) | (9.50%) | (9.64%) | (9.71%) | (12.40%) | (17.17%) |
Revenue per Share |
0.17 | (0.39) | (0.35) | 0.46 | (0.71) | (0.65) | (0.09) |
Operating CF per Share |
0.35 | (0.60) | (0.35) | (0.55) | (0.72) | (0.70) | (0.85) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
0.35 | (0.60) | (0.35) | (0.55) | (0.72) | (0.70) | (0.85) |
Cash per Share |
0.57 | 0.29 | 0.00 | 0.00 | 0.16 | 0.18 | 0.00 |
Shareholders Equity per Share |
4.01 | 3.65 | 3.49 | 3.41 | 3.98 | 5.24 | 7.09 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
4.01 | 3.65 | 3.49 | 3.41 | 3.98 | 5.24 | 7.09 |
Free Cash Flow |
1.32 | (2.27) | (1.32) | (2.08) | (2.82) | (2.83) | (3.46) |
Net Current Asset Value |
(5.28) | (5.55) | (4.56) | (1.44) | (0.88) | (3.83) | (1.29) |
EV/EBIT |
0.00 | 1.21 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||
Cash ROIC |
6.50% | (11.82%) | (7.51%) | (14.73%) | (17.10%) | (11.39%) | (11.46%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Average Payables |
0.00 | 0.03 | 0.03 | 0.00 | 0.00 | — | — |
Average Assets |
20.76 | 19.97 | 18.47 | 15.91 | 15.38 | 20.77 | 27.62 |
Average Common Equity |
14.89 | 14.55 | 13.41 | 12.91 | 14.22 | 18.41 | 25.06 |
Columns are period end dates